{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T02:20:00Z","timestamp":1776824400299,"version":"3.51.2"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,5,5]],"date-time":"2020-05-05T00:00:00Z","timestamp":1588636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,5,5]],"date-time":"2020-05-05T00:00:00Z","timestamp":1588636800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Res Cardiol"],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Coronary microvascular dysfunction (CMD) is present in various non-ischemic cardiomyopathies and in particular in those with left-ventricular hypertrophy. This study evaluated the diagnostic value of the novel cardiovascular magnetic resonance (CMR) parameter \u201cmyocardial transit-time\u201d (MyoTT) in distinguishing cardiac amyloidosis from other hypertrophic cardiomyopathies.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p><jats:italic>N\u2009=<\/jats:italic>\u200920 patients with biopsy-proven cardiac amyloidosis (CA), <jats:italic>N\u2009=<\/jats:italic>\u200920 patients with known hypertrophic cardiomyopathy (HCM), and <jats:italic>N\u2009=<\/jats:italic>\u200920 control patients without relevant cardiac disease underwent dedicated CMR studies on a 1.5-T MR scanner. The CMR protocol comprised cine and late-gadolinium-enhancement (LGE) imaging as well as first-pass perfusion acquisitions at rest for MyoTT measurement. MyoTT was defined as the blood circulation time from the orifice of the coronary arteries to the pooling in the coronary sinus (CS) reflecting the transit-time of gadolinium in the myocardial microvasculature.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>MyoTT was significantly prolonged in patients with CA compared to both groups: 14.8\u2009\u00b1\u20094.1\u00a0s in CA vs. 12.2\u2009\u00b1\u20092.5\u00a0s in HCM (<jats:italic>p\u2009=<\/jats:italic>\u20090.043) vs. 7.2\u2009\u00b1\u20092.6\u00a0s in controls (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). Native T1 and extracellular volume (ECV) were significantly higher in CA compared to HCM and controls (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). Both parameters were associated with a higher diagnostic accuracy in predicting the presence of CA compared to MyoTT: area under the curve (AUC) for native T1\u2009=\u20090.93 (95% confidence interval (CI)\u2009=\u20090.83\u20131.00; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) and AUC for ECV\u2009=\u20090.95 (95% CI\u2009=\u20090.88\u20131.00; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001)\u2014compared to the AUC for MyoTT\u2009=\u20090.76 (95% CI\u2009=\u20090.60\u20130.92; <jats:italic>p\u2009=<\/jats:italic>\u20090.008). In contrast, MyoTT performed better than all other CMR parameters in differentiating HCM from controls (AUC for MyoTT\u2009=\u20090.93; 95% CI\u2009=\u20090.81\u20131.00; <jats:italic>p\u2009=<\/jats:italic>\u20090.003 vs. AUC for native T1\u2009=\u20090.69; 95% CI\u2009=\u20090.44\u20130.93; <jats:italic>p\u2009=<\/jats:italic>\u20090.20 vs. AUC for ECV\u2009=\u20090.85; 95% CI\u2009=\u20090.66\u20131.00; <jats:italic>p\u2009=<\/jats:italic>\u20090.017).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The relative severity of CMD (measured by MyoTT) in relationship to extracellular changes (measured by native T1 and\/or ECV) is more pronounced in HCM compared to CA\u2014in spite of a higher absolute MyoTT value in CA patients. Hence, MyoTT may improve our understanding of the interplay between extracellular\/intracellular and intravasal changes that occur in the myocardium during the disease course of different cardiomyopathies.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00392-020-01661-6","type":"journal-article","created":{"date-parts":[[2020,5,5]],"date-time":"2020-05-05T22:03:32Z","timestamp":1588716212000},"page":"136-145","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Diagnostic value of the novel CMR parameter \u201cmyocardial transit-time\u201d (MyoTT) for the assessment of microvascular changes in cardiac amyloidosis and hypertrophic cardiomyopathy"],"prefix":"10.1007","volume":"110","author":[{"given":"Grigorios","family":"Chatzantonis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Bietenbeck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anca","family":"Florian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Meier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philipp","family":"Stalling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dennis","family":"Korthals","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Holger","family":"Reinecke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4526-8679","authenticated-orcid":false,"given":"Ali","family":"Yilmaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,5,5]]},"reference":[{"issue":"10","key":"1661_CR1","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1056\/NEJM196709072771006","volume":"277","author":"AS Cohen","year":"1967","unstructured":"Cohen AS (1967) Amyloidosis. N Engl J Med 277(10):522\u2013530 (contd)","journal-title":"N Engl J Med"},{"issue":"12","key":"1661_CR2","doi-asserted-by":"crossref","first-page":"e178","DOI":"10.1161\/CIRCULATIONAHA.111.069195","volume":"126","author":"CC Quarta","year":"2012","unstructured":"Quarta CC, Kruger JL, Falk RH (2012) Cardiac amyloidosis. Circulation 126(12):e178\u2013e182","journal-title":"Circulation"},{"issue":"36","key":"1661_CR3","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1200\/JCO.2011.37.7614","volume":"30","author":"G Palladini","year":"2012","unstructured":"Palladini G, Dispenzieri A, Gertz MA, Kumar S, Wechalekar A, Hawkins PN et al (2012) New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol 30(36):4541\u20134549","journal-title":"J Clin Oncol"},{"issue":"10","key":"1661_CR4","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1016\/j.amjcard.2012.06.059","volume":"110","author":"S Takashio","year":"2012","unstructured":"Takashio S, Izumiya Y, Jinnin M, Yamamuro M, Kojima S, Ihn H et al (2012) Diagnostic and prognostic value of subcutaneous tissue biopsy in patients with cardiac amyloidosis. Am J Cardiol 110(10):1507\u20131511","journal-title":"Am J Cardiol"},{"issue":"11","key":"1661_CR5","doi-asserted-by":"publisher","first-page":"282","DOI":"10.4414\/cvm.2018.00592","volume":"21","author":"S Brouwers","year":"2018","unstructured":"Brouwers S, Laptseva N, Gerber B, Schwotzer R, Ruschitzka F, Flammer JA (2018) Cardiac amyloidosis. Cardiovasc Med 21(11):282\u2013289. https:\/\/doi.org\/10.4414\/cvm.2018.00592","journal-title":"Cardiovasc Med"},{"issue":"4","key":"1661_CR6","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/0002-9149(75)90891-7","volume":"36","author":"C Chew","year":"1975","unstructured":"Chew C, Ziady GM, Raphael MJ, Oakley CM (1975) The functional defect in amyloid heart disease. The \"stiff heart\" syndrome. Am J Cardiol 36(4):438\u2013444","journal-title":"Am J Cardiol"},{"issue":"5","key":"1661_CR7","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/S0002-9149(77)80125-2","volume":"39","author":"RH Swanton","year":"1977","unstructured":"Swanton RH, Brooksby IA, Davies MJ, Coltart DJ, Jenkins BS, Webb-Peploe MM (1977) Systolic and diastolic ventricular function in cardiac amyloidosis. Studies in six cases diagnosed with endomyocardial biopsy. Am J Cardiol 39(5):658\u2013664","journal-title":"Am J Cardiol"},{"issue":"4","key":"1661_CR8","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S0025-7125(16)33009-7","volume":"51","author":"TR Kilpatrick","year":"1967","unstructured":"Kilpatrick TR, Horack HM, Moore CB (1967) \"Stiff heart\" syndrome. An uncommon cause of heart failure. Med Clin N Am 51(4):959\u2013966","journal-title":"Med Clin N Am"},{"issue":"4","key":"1661_CR9","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.pcad.2009.11.007","volume":"52","author":"RH Falk","year":"2010","unstructured":"Falk RH, Dubrey SW (2010) Amyloid heart disease. Prog Cardiovasc Dis 52(4):347\u2013361","journal-title":"Prog Cardiovasc Dis"},{"issue":"3","key":"1661_CR10","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/0002-9149(79)90389-8","volume":"44","author":"RR Smith","year":"1979","unstructured":"Smith RR, Hutchins GM (1979) Ischemic heart disease secondary to amyloidosis of intramyocardial arteries. Am J Cardiol 44(3):413\u2013417","journal-title":"Am J Cardiol"},{"issue":"4","key":"1661_CR11","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1161\/01.CIR.92.4.785","volume":"92","author":"BJ Maron","year":"1995","unstructured":"Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurosaki TT, Bild DE (1995) Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. Circulation 92(4):785\u2013789","journal-title":"Circulation"},{"issue":"9862","key":"1661_CR12","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/S0140-6736(12)60397-3","volume":"381","author":"BJ Maron","year":"2013","unstructured":"Maron BJ, Maron MS (2013) Hypertrophic cardiomyopathy. Lancet 381(9862):242\u2013255","journal-title":"Lancet"},{"issue":"12","key":"1661_CR13","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1056\/NEJM198903233201201","volume":"320","author":"P Spirito","year":"1989","unstructured":"Spirito P, Chiarella F, Carratino L, Berisso MZ, Bellotti P, Vecchio C (1989) Clinical course and prognosis of hypertrophic cardiomyopathy in an outpatient population. N Engl J Med 320(12):749\u2013755","journal-title":"N Engl J Med"},{"issue":"1","key":"1661_CR14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0300-8932(07)74976-X","volume":"60","author":"JC Moon","year":"2007","unstructured":"Moon JC (2007) What is late gadolinium enhancement in hypertrophic cardiomyopathy? Rev Esp Cardiol 60(1):1\u20134","journal-title":"Rev Esp Cardiol"},{"issue":"4","key":"1661_CR15","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1161\/01.CIR.59.4.689","volume":"59","author":"BJ Maron","year":"1979","unstructured":"Maron BJ, Roberts WC (1979) Quantitative analysis of cardiac muscle cell disorganization in the ventricular septum of patients with hypertrophic cardiomyopathy. Circulation 59(4):689\u2013706","journal-title":"Circulation"},{"issue":"8","key":"1661_CR16","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1053\/hupa.2000.16659","volume":"31","author":"C Basso","year":"2000","unstructured":"Basso C, Thiene G, Corrado D, Buja G, Melacini P, Nava A (2000) Hypertrophic cardiomyopathy and sudden death in the young: pathologic evidence of myocardial ischemia. Hum Pathol 31(8):988\u2013998","journal-title":"Hum Pathol"},{"issue":"3","key":"1661_CR17","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0735-1097(86)80181-4","volume":"8","author":"BJ Maron","year":"1986","unstructured":"Maron BJ, Wolfson JK, Epstein SE, Roberts WC (1986) Intramural (\"small vessel\") coronary artery disease in hypertrophic cardiomyopathy. J Am Coll Cardiol 8(3):545\u2013557","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"1661_CR18","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1016\/j.jcmg.2009.10.001","volume":"2","author":"DJ Pennell","year":"2009","unstructured":"Pennell DJ, Maceira AM (2009) Magnetic resonance imaging in cardiac amyloidosis. JACC Cardiovasc Imaging 2(12):1378\u20131380","journal-title":"JACC Cardiovasc Imaging"},{"issue":"2","key":"1661_CR19","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1161\/01.CIR.0000152819.97857.9D","volume":"111","author":"AM Maceira","year":"2005","unstructured":"Maceira AM, Joshi J, Prasad SK, Moon JC, Perugini E, Harding I et al (2005) Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 111(2):186\u2013193","journal-title":"Circulation"},{"issue":"4","key":"1661_CR20","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.amjcard.2008.09.105","volume":"103","author":"FL Ruberg","year":"2009","unstructured":"Ruberg FL, Appelbaum E, Davidoff R, Ozonoff A, Kissinger KV, Harrigan C et al (2009) Diagnostic and prognostic utility of cardiovascular magnetic resonance imaging in light-chain cardiac amyloidosis. Am J Cardiol 103(4):544\u2013549","journal-title":"Am J Cardiol"},{"issue":"12","key":"1661_CR21","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1016\/j.jcmg.2009.08.008","volume":"2","author":"BA Austin","year":"2009","unstructured":"Austin BA, Tang WH, Rodriguez ER, Tan C, Flamm SD, Taylor DO et al (2009) Delayed hyper-enhancement magnetic resonance imaging provides incremental diagnostic and prognostic utility in suspected cardiac amyloidosis. JACC Cardiovasc Imaging 2(12):1369\u20131377","journal-title":"JACC Cardiovasc Imaging"},{"key":"1661_CR22","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/1532-429X-10-54","volume":"10","author":"AM Maceira","year":"2008","unstructured":"Maceira AM, Prasad SK, Hawkins PN, Roughton M, Pennell DJ (2008) Cardiovascular magnetic resonance and prognosis in cardiac amyloidosis. J Cardiovasc Magn R 10:54","journal-title":"J Cardiovasc Magn R"},{"issue":"2","key":"1661_CR23","doi-asserted-by":"crossref","first-page":"120","DOI":"10.2463\/mrms.rev.2017-0145","volume":"17","author":"Y Amano","year":"2018","unstructured":"Amano Y, Kitamura M, Takano H, Yanagisawa F, Tachi M, Suzuki Y et al (2018) Cardiac MR imaging of hypertrophic cardiomyopathy: techniques, findings, and clinical relevance. Magn Reson Med Sci 17(2):120\u2013131","journal-title":"Magn Reson Med Sci"},{"issue":"3","key":"1661_CR24","doi-asserted-by":"crossref","first-page":"197","DOI":"10.15420\/aer.2016:13:3","volume":"5","author":"EJ Rowin","year":"2016","unstructured":"Rowin EJ, Maron MS (2016) The role of cardiac MRI in the diagnosis and risk stratification of hypertrophic cardiomyopathy. Arrhythm Electrophysiol Rev 5(3):197\u2013202","journal-title":"Arrhythm Electrophysiol Rev"},{"issue":"8","key":"1661_CR25","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1161\/CIRCULATIONAHA.117.032966","volume":"138","author":"A Axelsson Raja","year":"2018","unstructured":"Axelsson Raja A, Farhad H, Valente AM, Couce JP, Jefferies JL, Bundgaard H et al (2018) Prevalence and progression of late gadolinium enhancement in children and adolescents with hypertrophic cardiomyopathy. Circulation 138(8):782\u2013792","journal-title":"Circulation"},{"issue":"8","key":"1661_CR26","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.jacc.2018.05.060","volume":"72","author":"A Mentias","year":"2018","unstructured":"Mentias A, Raeisi-Giglou P, Smedira NG, Feng K, Sato K, Wazni O et al (2018) Late gadolinium enhancement in patients with hypertrophic cardiomyopathy and preserved systolic function. J Am Coll Cardiol 72(8):857\u2013870","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"1661_CR27","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1007\/s00392-018-1354-8","volume":"108","author":"S Rupp","year":"2019","unstructured":"Rupp S, Felimban M, Schanzer A, Schranz D, Marschall C, Zenker M et al (2019) Genetic basis of hypertrophic cardiomyopathy in children. Clin Res Cardiol 108(3):282\u2013289","journal-title":"Clin Res Cardiol"},{"issue":"4","key":"1661_CR28","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1007\/s00392-019-01530-x","volume":"109","author":"G Chatzantonis","year":"2020","unstructured":"Chatzantonis G, Bietenbeck M, Florian A, Meier C, Korthals D, Reinecke H et al (2020) \u201cMyocardial transit-time\u201d (MyoTT): a novel and easy-to-perform CMR parameter to assess microvascular disease. Clin Res Cardiol 109(4):488\u2013497. https:\/\/doi.org\/10.1007\/s00392-019-01530-x","journal-title":"Clin Res Cardiol"},{"issue":"8","key":"1661_CR29","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.jacc.2010.11.013","volume":"57","author":"N Mewton","year":"2011","unstructured":"Mewton N, Liu CY, Croisille P, Bluemke D, Lima JA (2011) Assessment of myocardial fibrosis with cardiovascular magnetic resonance. J Am Coll Cardiol 57(8):891\u2013903","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"1661_CR30","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1007\/s00392-018-1279-2","volume":"107","author":"M Bietenbeck","year":"2018","unstructured":"Bietenbeck M, Florian A, Shomanova Z, Meier C, Yilmaz A (2018) Reduced global myocardial perfusion reserve in DCM and HCM patients assessed by CMR-based velocity-encoded coronary sinus flow measurements and first-pass perfusion imaging. Clin Res Cardiol 107(11):1062\u20131070","journal-title":"Clin Res Cardiol"},{"issue":"4","key":"1661_CR31","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s10741-017-9628-1","volume":"22","author":"PE Bravo","year":"2017","unstructured":"Bravo PE, Di Carli MF, Dorbala S (2017) Role of PET to evaluate coronary microvascular dysfunction in non-ischemic cardiomyopathies. Heart Fail Rev 22(4):455\u2013464","journal-title":"Heart Fail Rev"},{"issue":"1","key":"1661_CR32","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s00392-017-1155-5","volume":"107","author":"F Sedaghat-Hamedani","year":"2018","unstructured":"Sedaghat-Hamedani F, Kayvanpour E, Tugrul OF, Lai A, Amr A, Haas J et al (2018) Clinical outcomes associated with sarcomere mutations in hypertrophic cardiomyopathy: a meta-analysis on 7675 individuals. Clin Res Cardiol 107(1):30\u201341","journal-title":"Clin Res Cardiol"},{"issue":"5","key":"1661_CR33","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.jacc.2005.10.050","volume":"47","author":"I Olivotto","year":"2006","unstructured":"Olivotto I, Cecchi F, Gistri R, Lorenzoni R, Chiriatti G, Girolami F et al (2006) Relevance of coronary microvascular flow impairment to long-term remodeling and systolic dysfunction in hypertrophic cardiomyopathy. J Am Coll Cardiol 47(5):1043\u20131048","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"1661_CR34","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.jchf.2014.03.009","volume":"2","author":"S Dorbala","year":"2014","unstructured":"Dorbala S, Vangala D, Bruyere J Jr, Quarta C, Kruger J, Padera R et al (2014) Coronary microvascular dysfunction is related to abnormalities in myocardial structure and function in cardiac amyloidosis. JACC Heart Fail 2(4):358\u2013367","journal-title":"JACC Heart Fail"},{"issue":"1","key":"1661_CR35","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s12968-017-0389-8","volume":"19","author":"DR Messroghli","year":"2017","unstructured":"Messroghli DR, Moon JC, Ferreira VM, Grosse-Wortmann L, He T, Kellman P et al (2017) Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2* and extracellular volume: a consensus statement by the Society for Cardiovascular Magnetic Resonance (SCMR) endorsed by the European Association for Cardiovascular Imaging (EACVI). J Cardiovasc Magn R 19(1):75","journal-title":"J Cardiovasc Magn R"},{"issue":"1","key":"1661_CR36","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s10554-016-0979-9","volume":"33","author":"K Parekh","year":"2017","unstructured":"Parekh K, Markl M, Deng J, de Freitas RA, Rigsby CK (2017) T1 mapping in children and young adults with hypertrophic cardiomyopathy. Int J Cardiovasc Imaging 33(1):109\u2013117","journal-title":"Int J Cardiovasc Imaging"},{"issue":"Suppl 1","key":"1661_CR37","doi-asserted-by":"crossref","first-page":"A1","DOI":"10.1136\/heartjnl-2017-311399.1","volume":"103","author":"T Kotecha","year":"2017","unstructured":"Kotecha T, Martinez-Naharro A, Treibel TA, Francis R, Nordin S, Abdel-Gadir A et al (2017) 001 Multiparametric mapping to understand pathophysiology in cardiac amyloidosis. Heart 103(Suppl 1):A1\u2013A2","journal-title":"Heart"},{"issue":"11","key":"1661_CR38","first-page":"1287","volume":"118","author":"MA Neben-Wittich","year":"2005","unstructured":"Neben-Wittich MA, Wittich CM, Mueller PS, Larson DR, Gertz MA, Edwards WD (2005) Obstructive intramural coronary amyloidosis and myocardial ischemia are common in primary amyloidosis. Am J Med 118(11):1287","journal-title":"Am J Med"},{"issue":"7","key":"1661_CR39","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1161\/CIRCRESAHA.117.311059","volume":"121","author":"AJ Marian","year":"2017","unstructured":"Marian AJ, Braunwald E (2017) Hypertrophic cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy. Circ Res 121(7):749\u2013770","journal-title":"Circ Res"},{"issue":"5 Pt 1","key":"1661_CR40","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1161\/01.CIR.88.5.2206","volume":"88","author":"S Betocchi","year":"1993","unstructured":"Betocchi S, Hess OM, Losi MA, Nonogi H, Krayenbuehl HP (1993) Regional left ventricular mechanics in hypertrophic cardiomyopathy. Circulation 88(5 Pt 1):2206\u20132214","journal-title":"Circulation"},{"issue":"10","key":"1661_CR41","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1016\/j.jcmg.2018.07.016","volume":"12","author":"A Tower-Rader","year":"2018","unstructured":"Tower-Rader A, Mohananey D, To A, Lever HM, Popovic ZB, Desai MY (2018) Prognostic value of global longitudinal strain in hypertrophic cardiomyopathy: a systematic review of existing literature. JACC Cardiovasc Imaging 12(10):1930\u20131942. https:\/\/doi.org\/10.1016\/j.jcmg.2018.07.016","journal-title":"JACC Cardiovasc Imaging"},{"issue":"4","key":"1661_CR42","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.jcmg.2009.11.013","volume":"3","author":"J Koyama","year":"2010","unstructured":"Koyama J, Falk RH (2010) Prognostic significance of strain Doppler imaging in light-chain amyloidosis. JACC Cardiovasc Imaging 3(4):333\u2013342","journal-title":"JACC Cardiovasc Imaging"},{"issue":"7","key":"1661_CR43","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s11912-017-0607-4","volume":"19","author":"M Tuzovic","year":"2017","unstructured":"Tuzovic M, Yang EH, Baas AS, Depasquale EC, Deng MC, Cruz D et al (2017) Cardiac amyloidosis: diagnosis and treatment strategies. Curr Oncol Rep 19(7):46","journal-title":"Curr Oncol Rep"},{"issue":"1","key":"1661_CR44","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1161\/CIRCULATIONAHA.118.038169","volume":"140","author":"T Lane","year":"2019","unstructured":"Lane T, Fontana M, Martinez-Naharro A, Quarta CC, Whelan CJ, Petrie A et al (2019) Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis. Circulation 140(1):16\u201326","journal-title":"Circulation"}],"container-title":["Clinical Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-020-01661-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00392-020-01661-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-020-01661-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,4]],"date-time":"2021-05-04T23:28:01Z","timestamp":1620170881000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00392-020-01661-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,5]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["1661"],"URL":"https:\/\/doi.org\/10.1007\/s00392-020-01661-6","relation":{},"ISSN":["1861-0684","1861-0692"],"issn-type":[{"value":"1861-0684","type":"print"},{"value":"1861-0692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,5]]},"assertion":[{"value":"4 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The author(s) declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study protocol complies with the Declaration of Helsinki. Written informed consent was obtained from every patient.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}